quetiapine 100 mg
1 INDICATIONS AND USAGE Quetiapine is an atypical antipsychotic indicated for the: Treatment of Schizophrenia (1.1) Adults: Efficacy was established in three 6-week clinical trials in patients with Schizophrenia (14.1) Acute treatment of manic episodes associated with Bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex (1.2) Adults: Efficacy was established in two 12-week monotherapy trials and in one 3-week adjunctive trial in patients with manic episodes associated with Bipolar I disorder (14.2) Acute treatment of depressive episodes associated with bipolar disorder (1.2) Adults: Efficacy was established in two 8-week trials in patients with bipolar I or II disorder (14.2) Maintenance treatment of bipolar disorder as an adjunct to lithium or divalproex (1.2) Adults: Efficacy was established in two maintenance trials in adults (14.2) 1.1 Schizophrenia Quetiapine fumarate tablets are indicated for the treatment of Schizophrenia. The efficacyof quetiapine in Schizophrenia was established in three 6 week trials in adults. The effectiveness of quetiapine for the maintenance treatment of Schizophrenia has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.1) ]. Pediatric use information in patients (13 to 17 years of age) with Schizophrenia is approved for AstraZeneca Pharmaceuticals LP’s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP’s marketing exclusivity rights; this drug product is not labeled for such use in those adolescent patients. 1.2 Bipolar Disorder Quetiapine fumarate tablets are indicated for the acute treatment of manic episodes associated with Bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, [see Clinical Studies (14.2) ]. Quetiapine fumarate tablets are indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [see Clinical Studies (14.2) ]. Quetiapine fumarate tablets are indicated for the maintenance treatment of Bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2)]. Pediatric use information in patients (10 to 17 years of age) with bipolar mania is approved for AstraZeneca Pharmaceuticals LP’s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP’s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I disorder Pediatric use information in patients (13 to 17 years of age) with Schizophrenia, and patients (10 to 17 years of age) with bipolar mania is approved for AstraZeneca Pharmaceuticals LP’s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP’s marketing exclusivity rights; this drug product is not labeled for such use in those patients.
physicians total care, inc.
ROUND YELLOW R 3
R 3 ROUND YELLOW
Related Pills
Clonazepam 1 MG Oral Tablet
Cardinal Health
Clonazepam 0.5 MG Oral Tablet
McKesson Contract Packaging
Clonazepam 2 MG Oral Tablet
Actavis Elizabeth LLC
Clonazepam 2 MG Oral Tablet
Actavis Elizabeth LLC
24 HR Seroquel 300 MG Extended Release Tablet
AstraZeneca Pharmaceuticals LP
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING Quetiapine fumarate tablets are available as 25 mg, white, round, biconvex, film coated tablets debossed with ‘R’ on one side and ‘1’ on other side and they are supplied in Bottles of 30 NDC 54868-6339-0 Quetiapine fumarate tablets 50 mg are white colored, round, biconvex, film coated tablets, debossed with ‘R’ on one side and ‘2’ on other side and they are supplied in Bottles of 30 NDC 54868-6340-0 Quetiapine fumarate tablets 100 mg are yellow colored, round, biconvex, film coated tablets debossed with ‘R’ on one side and ‘3’ on other side and they are supplied in Bottles of 30 NDC 54868-6338-0 Quetiapine fumarate tablets 200 mg are white, round, biconvex, film coated tablets, debossed with ‘R’ on one side and ‘5’ on other side and they are supplied in Bottles of 30 NDC 54868-6341-0 Quetiapine fumarate tablets 300 mg are white colored, modified capsule shaped, biconvex, film coated tablets, debossed with 'R' on one side and '6' on other side and they are supplied in Bottles of 30 NDC 54868-6342-1 Bottles of 60 NDC 54868-6342-0 Store at 20°-25°C (68°-77°F); [see USP Controlled Room Temperature]
More pills like ROUND R 3